Abbott Agrees to $670 Million Settlement to Resolve Infant Formula Litigation

Key Facts

In a move aimed at clearing long-standing legal hurdles, Abbott Laboratories has agreed to pay $670 million to resolve the Gill lawsuit and more than 2,000 other claims. These legal actions centered on allegations that the company's specialty preterm infant formulas were linked to necrotizing enterocolitis (NEC) in premature babies. According to reports, the company opted to bypass lengthy appeals processes to settle ongoing litigation and resolve thousands of pending claims simultaneously.

This settlement arrives at a critical juncture for the healthcare sector as companies look to mitigate legal risks associated with consumer products. Based on analyst assessments, while the settlement amount is significant, it provides essential legal certainty and removes a major overhang that has impacted investor sentiment. The agreement effectively addresses the bulk of the litigation surrounding the company's infant formula products and their alleged health impacts.

Based on data as of August 21, 2026, specific price levels for the instrument were unavailable in the current snapshot, necessitating a focus on qualitative price direction following the news. Investors should monitor broader market sentiment, particularly following the recent Michigan Consumer Sentiment reading of 51, which came in below forecasts and may influence the consumer and healthcare sectors in the near term.